Kenacort-A 10 (Triamcinolone Acetonide)

Triamcinolone acetonide binds to intracellular glucocorticoid receptors, forming a complex that enters the nucleus and alters gene transcription. This process suppresses the production of pro‑inflammatory cytokines, chemokines, and enzymes while enhancing anti‑inflammatory proteins, leading to decreased leukocyte migration, reduced edema, and overall immunosuppression at the site of injection.

The dose of Kenacort-A 10 is individualized by the prescribing clinician based on the specific indication, severity of disease, patient weight, and route of administration. The prescriber determines the volume and concentration to be injected, whether intra‑articular, intradermal, or intramuscular, and may adjust the regimen according to therapeutic response and safety monitoring.

Kenacort-A 10 is classified as Pregnancy Category C, meaning animal studies have shown some risk and there are no adequate human studies. It should be used only if the potential benefit justifies the potential risk to the fetus. Corticosteroids can be excreted in breast milk; therefore, caution is advised when administering to nursing mothers, and a risk‑benefit assessment should be performed.

To order Kenacort-A 10, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After receiving the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if required), and assist with import documentation.

Kenacort-A 10 (triamcinolone acetonide) is a medium‑ to high‑potency glucocorticoid, offering a longer duration of action than hydrocortisone and a slightly higher potency than methylprednisolone. Compared with dexamethasone, it has a lower mineralocorticoid effect, making it suitable for intra‑articular use where fluid retention is a concern. Choice of steroid depends on the clinical scenario, required potency, and safety profile.

Kenacort-A 10 should be stored at room temperature, preferably below 25 °C. Keep the vial in its original packaging, protect it from direct light, and avoid exposure to moisture. Do not freeze the solution. Before use, inspect the vial for particulate matter or discoloration; discard if any abnormalities are observed.

Kenacort-A 10 is supplied as a sterile injectable solution (10 mg/mL) and is administered by a qualified healthcare professional. It can be given intra‑articularly into a joint space, intradermally for skin lesions, or intramuscularly for deeper tissue involvement. The injection technique follows aseptic standards, and the volume injected is determined by the prescriber based on the target tissue and therapeutic goal.

Serious risks associated with Kenacort-A 10 include adrenal suppression, which can lead to cortisol deficiency, and severe infections due to immunosuppression. Other critical concerns are anaphylactic reactions, osteonecrosis of bone, and systemic hypercortisolism manifesting as hypertension, hyperglycaemia, or mood disturbances. Patients should be monitored for signs of infection, unexplained fatigue, or endocrine abnormalities.

Kenacort-A 10 is contraindicated in individuals with known hypersensitivity to triamcinolone acetonide or any component of the formulation, and in patients with systemic fungal infections that require systemic therapy. Caution is also advised for those with uncontrolled diabetes, active peptic ulcer disease, severe osteoporosis, or a history of avascular necrosis. The prescriber should evaluate each patient’s medical history before initiating therapy.